Table 1

Direct evidence of random-effects meta-analyses

Analysis	Figure	Outcome	RR	95% CI		p Value	I²
Analysis	Figure	Outcome	RR	Lower	Upper	p Value	I²
Oral ondansetron versus placebo
1.1	3.1.1	Cessation of vomiting	1.45	1.20	1.74	<0.001	61%
1.2	3.1.2	Cessation of vomiting—excluding Yilmaz et al17	1.33	1.19	1.49	<0.001	0%
2.1	4.1.1	Proportion with immediate IVT during the ED	0.41	0.29	0.59	<0.001	0%
2.2	4.1.2	Proportion with IVT up to 72 h (best–worst)	0.57	0.42	0.76	<0.001	0%
2.3	4.1.3	Proportion with IVT up to 72 h (worst–best)	0.53	0.39	0.72	<0.001	0%
3.1	5.1.1	Proportion admitted during the ED	0.43	0.18	1.00	0.05	17%
3.2	5.1.2	Proportion admitted up to 72 h (best–worst)	0.60	0.34	1.04	0.07	49%
3.3	5.1.3	Proportion admitted up to 72 h (worst–best)	0.73	0.43	1.23	0.24	0%
4.1	6	Revisit rate	1.24	0.49	3.15	0.66	28%
Intravenous ondansetron versus placebo
5.1	3.1.3	Cessation of vomiting	2.27	1.05	4.94	0.04	76%